Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Observational Study to Evaluate the Safety and Effectiveness of Cimzia in Rheumatoid Arthritis and Crohn's Disease Patients When Using a Comprehensive Program of Tuberculosis Screening and Monitoring

Next Previous
X
Search
Trial Profile

Observational Study to Evaluate the Safety and Effectiveness of Cimzia in Rheumatoid Arthritis and Crohn's Disease Patients When Using a Comprehensive Program of Tuberculosis Screening and Monitoring

Status: Discontinued
Phase of Trial: Phase IV

Latest Information Update: 07 Nov 2021

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Certolizumab pegol (Primary)
  • Indications Crohn's disease; Rheumatoid arthritis
  • Focus Adverse reactions
  • Sponsors UCB

    • Most Recent Events

    • 09 Nov 2015 Status changed from recruiting to discontinued as per ClinicalTrials.gov record.
    • 18 Aug 2014 Planned number of patients changed from 500 to 1070 as reported by ClinicalTrials.gov record.
    • 18 Jun 2014 Planned End Date changed from 1 Sep 2017 to 1 Dec 2020 as reported by ClinicalTrials.gov record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top